Snapshot from Jul 07, 2026 at 01:18 UTC. For live data and tracking: View Live
Entities / Nxera Pharma / Santhera Pharmaceuticals

Nxera Pharma & Santhera Pharmaceuticals

3 shared events · Importance 3 · Last updated Jun 02, 2026

Importance
3
Shared Events
3
Actions
0
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard
Shared Events (3)
30
Tech
AGAMREE Phase 1 Study Results
Nxera Pharma: Nxera Pharma holds commercialization rights for AGAMREE in Japan, South Korea, Australia, and New Zealand. Positive clinical data could support future market expansion in its licensed territories.
Santhera Pharmaceuticals: Santhera Pharmaceuticals is the developer of AGAMREE and benefits from positive clinical trial results, which could lead to expanded indications and increased sales-based milestone payments and royalties from its licensing partners.
Jul 01, 2026 · 6 articles
0
Business
Santhera Pharmaceuticals Appoints Orlando Oliveira CEO
Apr 23, 2026 · 6 articles
0
Business
Santhera Proposes Srishti Gupta Director
Apr 30, 2026 · 6 articles
NEWSDESK
Explore this relationship live

Track how Nxera Pharma and Santhera Pharmaceuticals interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.